Table 1

Schedule for measurement, testing and assessment at baseline and follow-up visits

MeasuresBaselineFollow-up
Anthropometric measures
 WeightXX
 HeightX
 BMI (kg/m2)XX
 Waist circumferenceXX
 Body composition (DXA)XX
Components of energy balance (antecedents to change in BMI)
 Dietary intake (1-weekday and 1-weekend day) by a registered dietitianXX
 Godin leisure time physical activity questionnaireXX
 Physical activity data captured via accelerometry (3-day period)XX
 Cardiorespiratory fitness (VO2 submax)XX
Tumour markers
 Ki-67, I-R, VEGF, TNFα, NFκB, 4E-BP1, activated caspase-3 and p16 in paraffin-embedded tumoursXX
p-Akt, p-GSK-3β, p-p70S6K, p-S6RP for fresh-frozen tumourX*X
Gene expression using multi array
 Insulin (I-R), leptin (LEPR), VEGF (VEGFR) and TNF (FAS) in tumoursXX
 Insulin (I-R), leptin (LEPR), VEGF (VEGFR), TNF (FAS) and apoptosis regulator (Bcl-2) in PBMCsXX
Serum biomarkers
 Insulin, leptin, estradiol, VEGF, TNFα, SHBGXX
Microbiome profiles
 SalivaXX
 FaecesXX
Quality of life
 FACT-B (questionnaire)XX
Demographics/comorbidities
 Demographics—race, age, educational levelX
 Medical history and medicationsXX
 OARS comorbidity scaleXX
  • *Diagnostic specimens are optionally obtained after study enrolment.

  • BMI, body mass index; DXA, dual-energy X-ray absorptiometry; FACT-B, Functional Assessment of Cancer Therapy Questionnaire for Breast Cancer; I-R, insulin receptor; LEPR, leptin receptor; NFκB, nuclear factor κ-light-chain-enhancer of activated B cells; OARS, Older American Resources and Services; PBMCs, peripheral blood mononuclear cells; SHBG, sex hormone-binding globulin; TNFα, tumour necrosis factor α; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.